MRC1 and endometrial cancer: We previously reported that loss of MMR protein expression was identified in 42 of 149 (28.2%) patients with endometrial cancer, and microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrioid endometrial cancer [37].